Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Ewing-like sarcoma Indication Strategy Report 2026: CIC-DUX4, Trials and Deals
30 July 2026
2026 Ewing-like sarcoma indication strategy covering epidemiology, CIC-DUX4 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Undifferentiated round cell sarcoma Indication Strategy Report 2026: NTRK, Trials and Deals
30 July 2026
2026 Undifferentiated round cell sarcoma indication strategy covering epidemiology, NTRK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Extraskeletal myxoid chondrosarcoma Indication Strategy Report 2026: NR4A3, Trials and Deals
30 July 2026
2026 Extraskeletal myxoid chondrosarcoma indication strategy covering epidemiology, NR4A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Microcystic adnexal carcinoma Indication Strategy Report 2026: Hedgehog, Trials and Deals
30 July 2026
2026 Microcystic adnexal carcinoma indication strategy covering epidemiology, Hedgehog biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Eccrine porocarcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
30 July 2026
2026 Eccrine porocarcinoma indication strategy covering epidemiology, EGFR biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Carcinoma ex pleomorphic adenoma Indication Strategy Report 2026: HER2, Trials and Deals
30 July 2026
2026 Carcinoma ex pleomorphic adenoma indication strategy covering epidemiology, HER2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Hidradenocarcinoma Indication Strategy Report 2026: HER2, Trials and Deals
30 July 2026
2026 Hidradenocarcinoma indication strategy covering epidemiology, HER2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Sebaceous carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
30 July 2026
2026 Sebaceous carcinoma indication strategy covering epidemiology, PD-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Adenoid cystic carcinoma of salivary gland Indication Strategy Report 2026: MYB, Trials and Deals
30 July 2026
2026 Adenoid cystic carcinoma of salivary gland indication strategy covering epidemiology, MYB biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Secretory carcinoma of salivary gland Indication Strategy Report 2026: NTRK3, Trials and Deals
30 July 2026
2026 Secretory carcinoma of salivary gland indication strategy covering epidemiology, NTRK3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Mammary analogue secretory carcinoma Indication Strategy Report 2026: NTRK3, Trials and Deals
30 July 2026
2026 Mammary analogue secretory carcinoma indication strategy covering epidemiology, NTRK3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Desmoplastic small round cell tumor Indication Strategy Report 2026: WT1, Trials and Deals
30 July 2026
2026 Desmoplastic small round cell tumor indication strategy covering epidemiology, WT1 biology, active trials, transactions, unmet need, competition and market…